Concepedia

Wen‐Kai Weng

WW

Statistics

Publications

44

Citations

4.1K

H-Index

24

Active since

2001

Affiliations

Stanford University(Current)

Stanford Medicine

Stanford Blood Center

Palo Alto University

Stanford Cancer Institute

Wen‐Kai Weng is an author at Stanford University specializing in immunology, hematology, and cancer immunotherapy.

ORCID

Publications per year

2001–2024

44

Publications

44

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Wen‐Kai Weng, Ronald Levy · Journal of Clinical Oncology · 2003 · 1.3K citations

, , +13

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Jay Y. Spiegel, Shabnum Patel, Lori Muffly et al. · Nature Medicine · 2021 · 572 citations · Full text

, , +17

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

Wen‐Kai Weng, Ronald Levy · Blood · 2001 · 216 citations · Full text

, , +16

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

John H. Baird, David J. Epstein, John Tamaresis et al. · Blood Advances · 2021 · 193 citations · Full text

, , +17

Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype

Wen‐Kai Weng, Debra K. Czerwinski, John M. Timmerman et al. · Journal of Clinical Oncology · 2004 · 192 citations

, , +17

1–5 of 44